ArticleBMC pulmonary medicine2026
A Body Shape Index and asthma prevalence in Chinese middle-aged and older adults: a cross-sectional study.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAsthma is a serious global health issue, and obesity is a crucial risk factor for asthma. A Body Shape Index (ABSI) is an innovative metric for evaluating obesity. This study aimed to investigate the association between ABSI and asthma prevalence among middle-aged and older adults in China.
methodsThis cross-sectional study retrieved data from the third wave of the China Health and Retirement Longitudinal Study (CHARLS). We investigated the relationship between ABSI and asthma prevalence using multivariable logistic regressions, stratified analyses, and restricted cubic splines. Sensitivity analyses were conducted to ensure the robustness of the results.
resultsThis study included 6,138 participants aged 45 years or older, among whom 365 were identified with asthma. A statistically significant association between ABSI Z-score and asthma was observed (adjusted odds ratio (OR) = 1.23, 95% CI: 1.06–1.42). A non-linear dose-response association was identified, with an inflection point at an ABSI Z-score of -0.523. For individuals with an ABSI Z-score ≥ -0.523, each unit increment in ABSI Z-score was associated with a 71% higher odds of asthma prevalence (OR = 1.71, 95% CI: 1.41–2.08). Significant interactions were observed in subgroups stratified by gender, smoking status, and marital status.
conclusionsThis study found a statistically significant association between ABSI and asthma prevalence in middle-aged and older Chinese. The data indicated that higher ABSI values were associated with increased asthma prevalence. Further prospective studies are warranted to elucidate temporal relationships and underlying causal mechanisms. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.